Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
Globe Newswire•04/11/2026•07:05 ET
2
Key Highlights
- ➤Q3 revenue $25.3 million, down 18.6% year over year
- ➤Q3 net loss $40.1 million, or $1.08 per diluted share
- ➤Q3 adjusted EBITDA $4.0 million, up $1.0 million year over year
- ➤Lifecore secured two technology transfer projects expected to contribute beginning in 2027
- ➤Early Q4 brought three development-phase programs, including Phase 2 and Phase 3 products
Expert Statements
Paul Josephs, President and chief executive officer of Lifecore Biomedical
“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027. In addition, early in the fourth quarter, we secured three new development-phase programs. These include one Phase 2 product with a top-20 global pharmaceutical company and two Phase 3 products with two biotech companies.”
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline --
CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026.
Get started
Create a free account to read the full story.